Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.

Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, Martinez F, Spaeder J, Weitz JI, Ye Z, Zannad F; AXIOM investigators.

Thromb Haemost. 2014 Jun;111(6):1141-52. doi: 10.1160/TH13-07-0543. Epub 2014 Mar 27.

PMID:
24671450
2.

Dabigatran versus warfarin in patients with atrial fibrillation.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators.

N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

3.

A case of vancomycin-resistant enterococcal endocarditis.

Brink AJ, van den Ende J, Routier RJ, Devenish L.

S Afr Med J. 2000 Nov;90(11):1113-5. No abstract available.

PMID:
11196031
4.

Difficulty in weaning from respiratory support in a patient with the intermediate syndrome of organophosphate poisoning.

Routier RJ, Lipman J, Brown K.

Crit Care Med. 1989 Oct;17(10):1075-6. No abstract available.

PMID:
2791572

Supplemental Content

Loading ...
Support Center